Analyst: Canopy Growth Looks Greener Than It Did 6 Weeks Ago

Over the past 12 months, Canopy Growth’s CGC shares have fallen by half. 

The Analyst

Bank of America Merrill Lynch’s Christopher Carey reiterated a Neutral rating on Canopy Growth with a $23 price objective. 

The Thesis

The risk-reward profile for Canopy's second-quarter looks much better than it did six weeks ago, Carey said in a Wednesday note. (See his track record here.) 

Bank of America downgraded the stock Sept. 27. 

The analyst predicts the company will reveal its new CEO when it reports second-quarter results Nov. 14.

That development, together with recently lowered estimates, could form a low bar, he said. 

“Reiterate Neutral, on near-term execution risks and potentially lofty Street estimates, balanced by an industry leading balance sheet.”

The second-quarter consensus sales estimate is CA$102 million ($77.4 million) versus CA$97 million in the prior quarter, Carey said. 

Bank of America is expecting a figure beneath the Street estimate: CA$94 million.

The Street's out-year estimates present a “best case scenario,” the analyst said. 

"While we think that setup has improved for FQ220, we view sustainable upside in Canopy shares as challenging, particularly against a backdrop of Street estimates that we think are too high."

Price Action

Canopy Growth shares were up 0.7% at $20 at the time of publication. 

Related Links: 

Cannabis Stock Gainers And Losers From November 5, 2019

Large Option Trader Betting On Canopy Growth Bounce Ahead Of Earnings